Helicobacter pylori chronically infects half of the human population and is associated with gastritis, peptic ulcer and gastric cancer. 13C-urea breath test (UBT) is the main in vivo tool for the diagnosis of H. pylori infection. In this study, the safety and the accuracy of UBT were evaluated.
Discovered in 1982 from human gastric biopsies, Helicobacter pylori is now widely acknowledged to be the major cause of gastric and duodenal ulcer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach (1) (2) (3) . It has been estimated that seven million cases of gastroduodenal diseases occur each year due to H. pylori infection, resulting in several thousands of deaths (4) . Recent studies suggest that the clinical outcome of H. pylori infection depends on both the pathogenicity of the infecting strain and the host cell-mediated response (5, 6) . Many virulence factors allow H. pylori to colonize the human gastric mucosa in spite of the unfavourable environment (7) (8) (9) (10) (11) (12) . Among these factors urease plays a prominent role since it metabolizes urea to carbon dioxide and ammonia able to buffer the gastric acidity (13) .
The intragastric 14C-urea hydrolysis in the cat was described almost 50 years ago and is likely due to the then unknown Helicobacter felis which could be suppressed by antibiotics (14) . Yet it was only in 1987 that urea breath test (UBT) with nonradioactive I3C was proposed as a diagnostic tool for detecting urea hydrolysis occurring in gastric H. pylori infection (15) . The principle behind UBT is very simple: in the presence of urease activity by H. pylori, isotopically labelled urease is rapidly hydrolysed and the released BC carbon dioxide is brought to the lungs and then exhaled in the expired breath, where it can be detected by mass-spectrophotometry.
The aim of this study was to assess the safety and the usefulness of I3C UBT in a large cohort of patients. A low dose of substrate (75 mg I3C-urea) was used combined with 10 ml citric (Table 1) . Only one patient reported moderate abdominal pain for 20 minutes after having drunk aqueous solution containing citric acid and l3Curea. Recently, a relationship between chronic urticaria and H. pylori infection was suggested, though no controlled study has yet been performed to prove this association (19) . In view of this, particular attention was paid to 53 dyspeptic patients with a history of chronic urticaria, food or drug intolerance. However, no allergic-type reactions or symptoms were recorded either in these or in any other patients studied. UBT was performed according to the manufacturerfs protocol (UREA l3C Breath Test, AB Analitica, Padua, Italy). Briefly, each patient was asked to provide two baseline breath samples before ingestion of 75 mg l3C urea diluted in 10 ml citric acid. Thirty minutes later, duplicate breath samples were collected (16) . l3CO~was measured as a ratio to I~C02 by isotopic ratio mass spectrometer (BreathMAT -TracerMAT, Finnigan MAT GmbH, Bremen, Germany). The Llvalues were expressed versus the international standard (17) . The algebraic difference between Ll-value found at 30 min after 13C urea ingestion and Ll-value at baseline is called DOB30 (Delta Over Base-line) and is expressed in per %0 value. UBT was considered positive when DOB30 was higher than 4%0. Any possible adverse reaction was carefully recorded in all 492 patients tested, in relation to the time of onset and the severity of the reaction. Therefore, systemic, gastrointestinal and allergic-type adverse symptoms were recorded 30 min, 60 min, I day and 7 days after UBT. Table 2 . Sensitivity, specificity, accuracy, and predictive values of I3C VBT for non-invasive detection of H. pylori infection.
MATERIAL AND METHODS
The first 256 patients examined in this study also underwent endoscopy. In this series of patients, two gastric biopsy specimens were taken from both the gastric corpus and the antrum and samples were processed for histological detection of H. pylori (18) Among the 256 patients (F/M = 1.5) tested 116 (45.3%) were H. pylori infected, whereas 140 (54.7%) had negative histology for H. pylori. No significant difference in the age nor in the gender was found between H. pylori infected and noninfected subjects. In the overall group of 492 patients, 225 (45.7%) were positive on UBT using 4 %0 as cut-off value for DOB30, whereas 267 (54.3%) were UBT-negative. A total number of 115 out of the 256 (44.9%) patients who underwent histological evaluation of H. pylori were positive on UBT. They included 113 patients with positive histology and 2 cases in which no evidence of H. pylori was found in the biopsy specimens examined (false positive on UBT). When compared to histology, however, there were only three false negative at UBT.
With 4 %0 as threshold value for DOB30, UBT accuracy was 98.04%. Sensitivity and specificity were 97.4%, 98.5%, respectively, with a positive predictive value and negative predictive value approaching 98.2%, and 97.8%, respectively ( Table 2 ).
DISCUSSION
Based on the above findings, UBT has proven to be a safe method for the diagnosis of gastric H. pylori infection. Compared to the radioactive 14C isotope, 13C is a non-radioactive, mass isotope of 12Carbonium, whose usage and handling are free of any drawbacks.
Compared to histology, UBT had similar accuracy for the diagnosis of gastric H. pylori infection, without being invasive (20) . The accuracy of the test, even performed one month after eradication therapy, is not affected by previous treatment with conventional antibiotic therapy, as demonstrated also in other studies (21, 22) . Considering that gastric H. pylori infection does not per se mean the presence of gastroduodenal disease and the detection of serum anti-H. pylori antibodies simply testifies that the host has "encountered" the bacterium at least once, UBT may represent an accurate and simple tool for noninvasive diagnosis. It may be particularly useful as a follow-up of patients with suspected H. pylori infection, particularly those who had already underwent explorative gastric endoscopy in the past few months.
Finally, the collection of samples for UBT has proven to be very easy and feasible in different out-patient departments or surgical suites. Centralization by mail to reference centers equipped with mass spectrometer would result in a dramatic reduction of the cost per each assay to the Health System.
